2/12/16
Curriculum Vitae
Name: Hsingjin Eugene Liu
Birthday: January 16, 1964
Current Address: Graduate Institute of Medical Research, Taipei Medical University,
250, Wushing Street, Taipei, Taiwan
Phone:
(Office) 011-886-22-930-7930ext 2553
(Fax) 011-886-28-663-8283
Email: liuxx086@tmu.edu.tw
Education and Training
1. Taipei Medical College, Department of Medicine, Doctor of Medicine (Sep. 1982~Jun. 1989).
2. Military Physician, Second Lieutenant (Aug.1989~Jun. 1991).
3. ECFMG certified (permanently validated).
4. Resident of Internal Medicine, Taipei Municipal Jen-Ai Hospital (Jul. 1991~Jun. 1994).
5. Chief Resident of Hemato-oncology, Taipei Municipal Jen-Ai Hospital (Jul. 1994~ Jun. 1995).
6. Ph. D. of Pathobiology Program, Dept. of Lab. Medicine and Pathology, University of Minnesota (Sep.
1995~Jun. 2000).
7. Clinical Fellow, Division of Hematology, Oncology and Transplantation, Department of Medicine,
University of Minnesota (July, 2000- July, 2002).
8. Assistant Professor, Graduate Institute of Biomedical Research, 2002-August~
Research Awards:
1. 2001 Cancer and Leukemia Foundation Group B (CALGB) Clinical Fellow Research Award
2. 2001 Minnesota Medical Foundation Transfusion Medicine Award
3. 2003 血液病學會研究發展獎
Publications:
Original articles
1. Chang JG, Liu HJ. Molecular diagnosis of thalassemia in Taiwan (Review). Kaohsiung Journal of Medical
Sciences 11(7):371-8, 1995.
1
2/12/16
2. Chang JG, Chang CP, Lu CM, Huang JM, Chen JT, Liu HJ. Rapid detection of hemoglobin variants by
mutagenically separated polymerase chain reaction (MS-PCR). Annals of Hematology 71(2): 97-100,1995.
3. 3. Kuo PL, Liu HJ, Chen JS, Wu RC, Lin SJ, Chang JG. Application of natural and amplification-created
restriction sites in prenatal and pre-implantation diagnosis of beta-thalassemia. Kaohsiung Journal of
Medical Sciences 11(9): 496-506, 1995.
4.Chang JG, Lu JM, Huang JM, Chen JT, Liu HJ, Chang CP. Rapid diagnosis of beta-thalassemia by
mutagenically separated polymerase chain reaction (MS-PCR) and its application to prenatal diagnosis.
British Journal of Haematology 91(3): 602-7, 1995.
5.Lin CP, Huang MJ, Liu HJ, Chang IY, Tsai CH. Successful treatment of acute promyelocytic leukemia in
a pregnant Jehovah's Witness with all-trans retinoic acid, rhG-CSF and erythropoietin [letter]. American
Journal of Hematology 51(3): 251:2, 1996.
6. Chang JG, Liu HJ, Huang JM, Yang TY, Chang CP. Multiplex mutagenically separated PCR: diagnosis of
beta-thalassemia and hemoglobin variants. Biotechniques 22 (3): 520-7, 1997.
7. Liu HJ, Hung YJ, Wissink S, Verfaillie CM. Improved retroviral transduction of hematopoietic progenitors
by combining methods to enhance virus-cell interaction. Leukemia 14(2): 307-11,2000.
8. Liu HJ. In vitro characterization of human hematopoietic stem cells. 2000 (PhD thesis)
9. Liu HJ, Verfaillie CM. Multipotent myeloid-lymphoid initiating cells (ML-IC) are highly enriched in the
rhodamine-, c-kit+CD33-CD38- fraction of umbilical cord CD34+ cells. Experimental Hematology
30:582-589,2002.
10. Huang MJ, Hsieh RK, Lin CP, Chang IY, Liu HJ. The cytotoxicity of arsenic trioxide in normal
hematopoietic progenitors and leukemic cells are dependent on their cell-cycle status. Leukemia and
Lymphoma 43:2191-2199, 2002.
11. Liu H, Huang MJ. Targeting EGFR mutations in lung cancer: a perspective from Asia-Pacific region.
Asian Pacific Journal of Clinical Oncology. (in press)
Meeting abstracts:
1. Chang JG, Chen TP, Lo YS, Sy WD, Liu HJ, Chiou SS. Molecular and clinical characterization of G6PD
deficiency in the Chinese infants with or without severe neonatal hyperbilirubinemia. Blood 82(11)
suppl:463a, 1993.
2. Chang JG, Lin SF, Chen JT, Chan CP, Liu HJ. Molecular diagnosis of beta-thalassemia by multiplex
mutagenically separated polymerase chain reaction (multiplex MS-PCR). Blood 84(11) suppl:261a, 1994.
3. Chang JG, Huang JM, Yang TY, Liu HJ. Detection of ras mutation by degenerate mutagenically separated
PCR. American Journal of Human Genetics 57 suppl: a62, 1995.
2
2/12/16
4.Liu HJ, Punzel M, Moore KA, Verfaillie CM. Induction of proliferation of HPCs alone does not improve
retroviral transduction. Blood 90(10) suppl:118a, 1997.
5. Liu HJ, Hung YJ, Verfaillie CM. Cationic lipids, recombinant fibronectin fragment (CH296) and transwell
flow-through system synergistically augment CD34+ cell retroviral transduction efficiency. Blood 92(10)
suppl: 147a, 1998.
6. Liu HJ, Verfaillie CM. In vitro characterization of human self-renewing multilineage hematopoietic stem
cells. Blood 94 (10) suppl1: 31a, 1999
7. 7. Liu HJ, Wagner EJ, Petkov BI, Eide CR, Verfaillie CM. Apoptosis and poor proliferation in the absence
of stroma is responsible for poor retroviral gene transfer in CD34+ progenitors from Fanconi anemia. Blood
96 (11 suppl): 230a, 2000.
8. Liu HJ, Verfaillie CM. ML-IC are highly enriched in the rhodamine-, c-kit +, CD38- fraction of umbilical
cord CD34+ cell. Blood 96 (11 suppl): 664a, 2000.
9. Liu HJ, Verfaillie CM. Phenotypic and in vitro characterization of Hoechst 33342 side population in
umbilical cord blood. Blood 96 (11 suppl): 664a, 2000.
10. Liu HJ, Wagner JE, Pektov A, Eide C, Verfaillie CM. Hematopoietic progenitors from Fanconi anemia
can be successfully transduced by a lentiviral vector in short-term stroma-free culture without the loss of CFC
and LTC-IC. Blood 98(11) suppl: 214a, 2001.
11. Liu HJ, Verfaillie CM. Maintenance of multiple self-renewal of myeloid-lymphoid initiating cells in
AFT024-containing contact culture. Blood 98(11) suppl: 274a, 2001.
12. Leung AYH, Eckfeldt CE, Liu EHJ, Verfaillie CM. Differential gene expression of primitive
hematopoietic stem/progenitor cells derived from human umbilical cord blood. Abstract 2842, Annual
meeting of American Society of Hematology, 2002.
13. Liu HJ, Lamming CE, Verfaillie CM. An AFT024-containing in vitro culture to assess self-renewal and
multilineage differentiation of NOD/SCID repopulating hematopoietic stem cells. Abs 4097, Annual meeting
of American Society of Hematology, 2002.
14. Liu HJ, Lin CP, IY Chang, Shih D, Huang MJ. Differing mechanisms of drug resistance to arsenic
trioxide between primitive CD34(+) hematopoietic progenitors and mature CD3(+) T cells. Abs 4398,
Annual meeting of American Society of Hematology, 2002.
15. Huang MJ, Lin SF, Lin CP, Liu CR, Chow JM, Liu HJ. Peripheral Blood CD3+ T cells, independent on
their cell-cycle status, are inherently resistant to high concentrations of arsenic trioxide. European Journal of
Cancer 1 suppl S167, 2003.
3
2/12/16
16. Lin YY, Lin SF, Huang MJ, Lin CP, Lu JD, Chow JM, Liu HJ. Arsenic trioxide can partially but not
completely eradicate leukemic cells in the NOD/SCID animal model of human acute myeloid leukemia. 8 th
Annual joint meeting of Taiwan Cancer Society, 2003.
16. Huang MJ, Lin YY, Lin SF, Chow JM, Lin CP, Liu CR, Hsieh RK, Liu HE. Bone marrow
microenvironment maintains the leukemic cells in G0/G1 phase and mediates the drug resistance to arsenic
trioxide. Blood 102 suppl: 592a, 2003.
17. Lin S, Huang MJ, Liu CR, Chow JM, Lin CP, Liu HE. A comparative study of various histone
deacetylase inhibitors on the proliferation, differentiation and apoptosis of human acute myeloid leukemia.
第九屆台灣癌症聯合學術年會 A24, 2004.
4